Asia Pacific Infectious Disease Therapeutics Market
No. of Pages: 101 | Report Code: BMIRE00030366 | Category: Life Sciences
No. of Pages: 101 | Report Code: BMIRE00030366 | Category: Life Sciences
The Asia Pacific infectious disease therapeutics market was valued at US$ 25,904.61 million in 2022 and is expected to reach US$ 37,415.07 million by 2030; it is estimated to register a CAGR of 4.7% from 2022 to 2030.Growing Opportunities in Developing Nations Boost Asia Pacific Infectious Disease Therapeutics Market
The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. Asia Pacific has become an adaptable and business-friendly hub due to moderately fewer data requirements and stringent regulations. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is calling for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries in the AIDS response. Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in India and South Korea, are expected to witness lucrative opportunities in the future. This is owing to the high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improving infrastructure of healthcare; and growing medical tourism in these countries.Asia Pacific Infectious Disease Therapeutics Market Overview
The Asia Pacific infectious disease therapeutics market is sub-segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR during the forecast period. The market in the region is expected to grow owing to rising global healthcare expenditure, increasing incidence of chronic and infectious diseases, and a growing geriatric population base. The infectious disease such as influenza, hepatitis B, and infectious diarrhea are common in China and typhoid, malaria, jaundice, tuberculosis, and AIDS in India. Influenza, hepatitis B, and infectious diarrhea are the three common infectious diseases in China. As stated by Frontiers Public Health, the winter peak of influenza coincided with the outbreak of COVID-19 in the country in 2021. According to the World Bank Country Director of China 2020, the country is at a high risk of infectious diseases due to its growing population, wildlife abundance, habitat fragmentation, and high livestock production levels. Considering the country's growing incidence of infectious diseases, the World Bank's Board of Executive Directors approved a US$ 300 million loan for the Emerging Infectious Diseases Prevention, Preparedness and Response Project. This will help it reduce the risk of zoonotic and other emerging health threats. Thus, the rising incidence of infectious diseases and measures taken to control these diseases are expected to boost the China infectious disease therapeutics market in the coming years.
Asia Pacific Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
Strategic insights for the Asia Pacific Infectious Disease Therapeutics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Asia Pacific Infectious Disease Therapeutics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
Get more information on this report Asia Pacific Infectious Disease Therapeutics Strategic Insights
Get more information on this report Asia Pacific Infectious Disease Therapeutics Report Scope
Report Attribute
Details
Market size in 2022
US$ 25,904.61 Million
Market Size by 2030
US$ 37,415.07 Million
Global CAGR (2022 - 2030)
4.7%
Historical Data
2020-2021
Forecast period
2023-2030
Segments Covered
By Drug Class
By Indication
By Distribution Channel
Regions and Countries Covered
Asia-Pacific
Market leaders and key company profiles
Get more information on this report Asia Pacific Infectious Disease Therapeutics Regional Insights
Get more information on this report
Asia Pacific Infectious Disease Therapeutics Market Segmentation
The Asia Pacific infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.
Based on drug class, the Asia Pacific infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.
In terms of indication, the Asia Pacific infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.
Based on route of administration, the Asia Pacific infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.
In terms of distribution channel, the Asia Pacific infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.
By country, the Asia Pacific infectious disease therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific infectious disease therapeutics market share in 2022.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the Asia Pacific infectious disease therapeutics market.
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. F. Hoffmann-La Roche Ltd
5. Gilead Sciences Inc
6. GSK Plc
7. Merck & Co Inc
8. Pfizer Inc
9. Shionogi & Co Ltd
The Asia Pacific Infectious Disease Therapeutics Market is valued at US$ 25,904.61 Million in 2022, it is projected to reach US$ 37,415.07 Million by 2030.
As per our report Asia Pacific Infectious Disease Therapeutics Market, the market size is valued at US$ 25,904.61 Million in 2022, projecting it to reach US$ 37,415.07 Million by 2030. This translates to a CAGR of approximately 4.7% during the forecast period.
The Asia Pacific Infectious Disease Therapeutics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Infectious Disease Therapeutics Market report:
The Asia Pacific Infectious Disease Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Infectious Disease Therapeutics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Infectious Disease Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Infectious Disease Therapeutics Market
